Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study
PLOS Medicine · 2024
DOI: 10.1371/journal.pmed.1004457 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS Medicine, 2024. Verfasst von Yuqi Hu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Clozapine, Schizophrenia, Hematologic Neoplasms, Antipsychotic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation and Technology Commission - Hong Kong.
Abstract (Originalsprache)
Background
Clozapine is widely regarded as a highly efficacious psychotropic drug that is largely underused worldwide. Recent disproportionality analyses and nationwide case-control studies suggested a potential association between clozapine use and hematological malignancy (HM). Nevertheless, the absolute rate difference is not well-established due to the absence of analytic cohort studies. The clinical significance of such a potential risk remains unclear. Methods and findings We extracted data from a territory-wide public healthcare database from January 2001 to August 2022 in Hong Kong to conduct a retrospective cohort study of anonymized patients aged 18 + years with a diagnosis of schizophrenia who used clozapine or olanzapine (drug comparator with highly similar chemical structure and pharmacological mechanisms) for 90 + days, with at least 2 prior other antipsychotic use records within both groups. Weighted by inverse probability of treatment (IPTW) based on propensity scores, Poisson regression was used to estimate the incidence rate ratio (IRR) of HM between clozapine and olanzapine users. The absolute rate difference was also estimated. In total, 9,965 patients with a median follow-up period of 6.99 years (25th to 75th percentile: 4.45 to 10.32 years) were included, among which 834 were clozapine users. After IPTW, the demographic and clinical characteristics of clozapine users were comparable to those of olanzapine users. Clozapine users had a significant weighted IRR of 2.22 (95% confidence interval (CI) [1.52, 3.34]; p < 0.001) for HM compared to olanzapine users. The absolute rate difference was estimated at 57.40 (95% CI [33.24, 81.55]) per 100,000 person-years. Findings were consistent across subgroups by age and sex. Sensitivity analyses all supported the robustness of the results and showed good specificity to HM but no other cancers. The main limitation of this observational study is the potential residual confounding effects that could have arisen from the lack of randomization in clozapine or olanzapine use.
Conclusions
Absolute rate difference in HM incidence associated with clozapine is small despite a 2-fold elevated rate. Given the rarity of HM and existing blood monitoring requirements, more restrictive indication for clozapine or special warnings may not be necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
- Department of Pharmacy Administration, School of Pharmacy, Xi'an Jiaotong University, Shaanxi, China.
- Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Shaanxi, China.
- Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Sha Tin, Hong Kong SAR.
- Department of Psychiatry, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
- Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
ORCID-Profile: Yuqi Hu, Le Gao, Lingyue Zhou, Cuiling Wei, Franco Wing Tak Cheng, Amy Pui Pui Ng, Heidi Ka Ying Lo, Krystal Chi Kei Lee, Wing Chung Chang, William Chi Wai Wong, Esther Wai Yin Chan, Ian Chi Kei Wong, Yi Chai, Francisco Tsz Tsun Lai
Förderung
- Innovation and Technology Commission - Hong Kong
Zitieren
APA
Hu, Y., Gao, L., Zhou, L., Liu, W., Wei, C., Liu, B., Sun, Q., Tian, W., Chu, R. Y. K., Song, S., Cheng, F. W. T., Chan, J. K. N., Ng, A. P. P., Lo, H. K. Y., Lee, K. C. K., Chang, W. C., Wong, W. C. W., Chan, E. W. Y., Wong, I. C. K., …, & Lai, F. T. T. (2024). Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004457
Vancouver
Hu Y, Gao L, Zhou L, Liu W, Wei C, Liu B, et al. Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study. PLOS Medicine. 2024. doi:10.1371/journal.pmed.1004457
BibTeX
@article{Hu2024,
author = {Hu, Yuqi and Gao, Le and Zhou, Lingyue and Liu, Wenlong and Wei, Cuiling and Liu, Boyan and Sun, Qi and Tian, Wenxin and Chu, Rachel Yui Ki and Song, Song and Cheng, Franco Wing Tak and Chan, Joe Kwun Nam and Ng, Amy Pui Pui and Lo, Heidi Ka Ying and Lee, Krystal Chi Kei and Chang, Wing Chung and Wong, William Chi Wai and Chan, Esther Wai Yin and Wong, Ian Chi Kei and Chai, Yi and Lai, Francisco Tsz Tsun},
title = {Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: A population cohort study},
journal = {PLOS Medicine},
year = {2024},
doi = {10.1371/journal.pmed.1004457}
}
EUVIMED